Navigation Links
New approach to Alzheimer's therapy
Date:7/30/2010

The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.

DZNE and LMU researchers have succeeded in identifying an enzyme known as alpha secretase, which cleaves the amyloid precursor protein (APP) without forming beta-amyloid. Up to this point three different candidates for this function had been under consideration, but the research team has now been able to show that the enzyme ADAM10 alone is responsible for the specific cleavage. Dr. Stefan Lichtenthaler and his team developed highly specific antibodies that can identify the different cleavage products of the precursor protein in the brain cells of mice and in human cell cultures. Using a special technique called RNA interference, the researchers managed to block each of the three genes that code for the three ADAM enzymes under suspicion. An analysis of the cleavage products revealed that the ADAM10 gene was the only one able to prevent the formation of beta-amyloids. They confirmed their results using mass spectrometry.

"In ADAM10 we have identified a target molecule that plays a central role in the development of the molecular processes in Alzheimer's disease. We know that ADAM10 is less active in Alzheimer patients," says Dr. Lichtenthaler. When ADAM10 is less active, the precursor protein is more likely to be cleaved in a way that promotes the formation of beta-amyloids.

"It is possible that less ADAM10 activity could increase susceptibility to Alzheimer's disease. If that is the case, stimulating ADAM10 could be an important mechanism for therapy. But our antibodies also open up new possibilities for diagnosing and preventing the disease," says Lichtenthaler. The antibodies could be used to measure ADAM10 activity in spinal fluid and, by extension, identify persons who may have an increased risk of developing Alzheimer's disease. A series of experiments to examine this possibility is already underway.


'/>"/>

Contact: Sonja Juelich-Abbas
sonja.juelich-abbas@dzne.de
49-228-433-02260
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Discovery points to new approach for diabetes therapy
2. Personalized approach to smoking cessation may be reality in 3-5 years
3. Stem-cell therapy may provide new approach to fight infection
4. Insight into cells could lead to new approach to medicines
5. Entrust Credentialing Services - A New End-to-End, SAAS Approach for Identity-Based Smartcards
6. No more pills: Male contraceptive takes new approach
7. Epigenetic concepts offer new approach to degenerative disease
8. Dual approach gives a more accurate picture of the autistic brain
9. Development of new anti-cancer gene therapy approach using lentiviral vectors
10. Asexual plant reproduction may seed new approach for agriculture
11. Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... ... Back pain relief technology is now available without a prescription at What ... relief for WAR members. , This spinal restoration platform boasts utilization of technology that ... suffering from chronic back pain. , What A Relief Back Pain Centers ...
(Date:1/11/2017)... , PITTSBURGH and BENGALURU, ... (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, ... Drug Administration (FDA) has accepted Mylan,s biologics license application ... through the 351(k) pathway. This product is a proposed ... certain HER2-positive breast cancers. The anticipated FDA goal date ...
(Date:1/11/2017)... , Jan. 11, 2017  GenVec, Inc. ... delivery company, announced today that its chief scientific ... a talk entitled  "AdenoVerse™ platform for translational development ... Biotech Showcase at the upcoming Phacilitate Cell & ... Miami , Florida.  Dr. Brough,s presentation will ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... signed a multi-year license agreement with Poseida Therapeutics Inc, the San Diego based ... genetic data. Poseida Therapeutics selected KBioBox in order to harness KBioBox’s powerful BioEngine ...
Breaking Biology Technology: